
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc. has upgraded its GMP facilities to enhance manufacturing capacity ahead of the anticipated launch of PRGN-2012 in the second half of 2025, which positions the company to meet projected demand effectively. Management's proprietary market analysis estimates that PRGN-2012 could generate risk-adjusted revenues of $93 million by 2026, with substantial growth expected to reach $969 million by 2033, indicating a strong market opportunity. Recent adjustments to financial projections, including an increase in the annual price estimate for PRGN-2012 and operational expense adjustments, reflect a commitment to optimizing the company's financial performance ahead of the product's anticipated robust launch.
Bears say
Precigen Inc has faced challenges in establishing reliable revenue streams, as its reliance on collaborations with partners for technology access fees and milestones creates inherent volatility in its income. The company's focus on developing complex synthetic biology solutions has not yet translated into a sustainable or profitable business model, raising concerns about its long-term financial viability. Furthermore, the competitive landscape in the biotechnology sector, coupled with the high costs associated with research and development, contributes to a negative outlook on Precigen's stock performance.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares